Share Price | Agilon Health, Inc. Stock Analysis & Recommendation

Q: What does Agilon Health, Inc. do?

Overview: Agilon Health, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a small-cap company.Financial Snapshot: Most recent Net Sales: 1,533 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) Market cap: USD 869.30 Million (Small Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.67 Return on Equity: -49.80% Price to Book: 1.74Contact Details: Registrar Address: Not available.

Q: Is Agilon Health, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Agilon Health, Inc. has changed from mildly bearish to bearish. The weekly MACD is bearish, and the daily moving averages also indicate a bearish stance. The Bollinger Bands are showing a mildly bearish trend on the weekly and a bearish trend on the monthly. The KST is bearish on the weekly and mildly bullish on the monthly, while the Dow Theory shows no trend in both weekly and monthly time frames. In terms of performance, Agilon Health has significantly underperformed compared to the S&P 500, with a year-to-date return of -38.42% versus the S&P 500's 12.22%, and a one-year return of -70.68% compared to 17.14% for the index. Overall, the current technical stance is bearish, indicating weakness in the stock's performance.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

88.65 k

Shareholding (Mar 2026)

FII

9.12%

Held by 126 FIIs

DII

66.77%

Held by 64 DIIs

Promoter

24.10%

How big is Agilon Health, Inc.?

22-Jun-2025

As of Jun 18, Agilon Health, Inc. has a market capitalization of 869.30 million, with net sales of 5,988.96 million and a net profit of -255.41 million over the latest four quarters.

View full answer

What does Agilon Health, Inc. do?

22-Jun-2025

Agilon Health, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1.533 billion and a net profit loss of $2 million as of March 2025. Key metrics include a market cap of $869.30 million, a negative P/E ratio, and a dividend yield of 0.00%.

View full answer

Is Agilon Health, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Agilon Health, Inc. is in a bearish trend with significant underperformance, showing a year-to-date return of -38.42% compared to the S&P 500's 12.22%.

View full answer

Compare Agilon Health, Inc. with Similar Stocks

DaVita, Inc.Encompass Health Corp.Acadia Healthcare Co., Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Negative results in Jun 25

PRE-TAX PROFIT(Q) At USD -104.19 MM has Fallen at -68.49%
NET PROFIT(Q) At USD -104.25 MM has Fallen at -67.37%
ROCE(HY) Lowest at -60.64%

Risky - Negative EBITDA

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 247 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.90

Return on Equity

-102.82%

Price to Book

0.81

Revenue and Profits:

Net Sales:

1,420 Million

(Quarterly Results - Mar 2026)

Net Profit:

30 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

689.67%

6 Months

456.1%

1 Year

57.07%

2 Years

-42.31%

3 Years

-83.58%

4 Years

-82.28%

5 Years

-89.85%

Agilon Health, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

36.57%

EBIT Growth (5y)

1.05%

EBIT to Interest (avg)

-41.06

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.07

Sales to Capital Employed (avg)

9.23

Tax Ratio

0.70%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.81

EV to EBIT

0.08

EV to EBITDA

0.08

EV to Capital Employed

-0.96

EV to Sales

-0.00

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-102.82%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 57 Schemes (62.56%)

Foreign Institutions

Held by 126 Foreign Institutions (9.12%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -9.49% vs 9.35% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 115.83% vs -71.42% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,420.50",
          "val2": "1,569.50",
          "chgp": "-9.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "16.90",
          "val2": "-149.40",
          "chgp": "111.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.80",
          "val2": "1.70",
          "chgp": "5.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.10",
          "val2": "-37.40",
          "chgp": "83.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "29.90",
          "val2": "-188.90",
          "chgp": "115.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "7.10%",
          "val2": "-99.70%",
          "chgp": "10.68%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -2.11% vs 40.41% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -61.93% vs -28.16% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,932.60",
          "val2": "6,060.50",
          "chgp": "-2.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-392.50",
          "val2": "-259.50",
          "chgp": "-51.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "6.60",
          "val2": "6.20",
          "chgp": "6.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-42.20",
          "val2": "-8.20",
          "chgp": "-414.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-405.30",
          "val2": "-250.30",
          "chgp": "-61.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-71.00%",
          "val2": "-46.90%",
          "chgp": "-2.41%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

1,420.50

1,569.50

-9.49%

Operating Profit (PBDIT) excl Other Income

16.90

-149.40

111.31%

Interest

1.80

1.70

5.88%

Exceptional Items

-6.10

-37.40

83.69%

Consolidate Net Profit

29.90

-188.90

115.83%

Operating Profit Margin (Excl OI)

7.10%

-99.70%

10.68%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is -9.49% vs 9.35% in Dec 2025

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is 115.83% vs -71.42% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

5,932.60

6,060.50

-2.11%

Operating Profit (PBDIT) excl Other Income

-392.50

-259.50

-51.25%

Interest

6.60

6.20

6.45%

Exceptional Items

-42.20

-8.20

-414.63%

Consolidate Net Profit

-405.30

-250.30

-61.93%

Operating Profit Margin (Excl OI)

-71.00%

-46.90%

-2.41%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -2.11% vs 40.41% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -61.93% vs -28.16% in Dec 2024

All Annual Results

Company CV

About Agilon Health, Inc.

Agilon Health, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available